Literature DB >> 31067448

A Big Win for Diabetic Kidney Disease: CREDENCE.

David Z I Cherney1, Ayodele Odutayo2, Subodh Verma3.   

Abstract

Diabetic kidney disease (DKD), a major cause of morbidity, mortality, and economic hardship globally, is on the rise. The results of the recently reported CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial have ushered in hope and optimism for the treatment of DKD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31067448     DOI： 10.1016/j.cmet.2019.04.011

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  9 in total

Review 1.  Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Authors:  Kevin Yau; Atit Dharia; Ibrahim Alrowiyti; David Z I Cherney
Journal:  Kidney Int Rep       Date:  2022-05-05

2.  Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota.

Authors:  Qian Chen; Dongwen Ren; Jiaqi Wu; Haiyang Yu; Xiaopeng Chen; Jia Wang; Yi Zhang; Mengyang Liu; Tao Wang
Journal:  J Nat Med       Date:  2020-09-30       Impact factor: 2.343

Review 3.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

4.  Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.

Authors:  Ayodele Odutayo; Bruno R da Costa; Tiago V Pereira; Vinay Garg; Samir Iskander; Fatimah Roble; Rahim Lalji; Cesar A Hincapié; Aquila Akingbade; Myanca Rodrigues; Arnav Agarwal; Bishoy Lawendy; Pakeezah Saadat; Jacob A Udell; Francesco Cosentino; Peter J Grant; Subodh Verma; Peter Jüni
Journal:  J Am Heart Assoc       Date:  2021-09-13       Impact factor: 5.501

5.  The hidden diabetic kidney disease in a university hospital-based population: a real-world data analysis.

Authors:  María Marques; Paula López-Sánchez; Fernando Tornero; Pedro Gargantilla; Alba Maroto; Alberto Ortiz; José Portolés
Journal:  Clin Kidney J       Date:  2022-04-14

Review 6.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

Review 7.  Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class.

Authors:  Hideaki Kaneto; Atsushi Obata; Tomohiko Kimura; Masashi Shimoda; Tomoe Kinoshita; Taka-Aki Matsuoka; Kohei Kaku
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

8.  Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.

Authors:  Matthew R Weir; April Slee; Tao Sun; Dainius Balis; Richard Oh; Dick de Zeeuw; Vlado Perkovic
Journal:  Clin Kidney J       Date:  2020-09-02

Review 9.  Lipid mediators of insulin signaling in diabetic kidney disease.

Authors:  Alla Mitrofanova; Marie Anne Sosa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.